Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

AmeriSource Expects Post-Merger Market Share Of 33% To Pass FTC Review

This article was originally published in The Tan Sheet

Executive Summary

AmeriSource and Bergen Brunswig predict the Federal Trade Commission will accept their combined 33% market share in the drug wholesaling sector without initiating an antitrust challenge.

You may also be interested in...



AmerisourceBergen Merger Complete, FTC Says Efficiencies Justify Approval

Federal Trade Commission approval of the merger of AmeriSource and Bergen Brunswig reflects the agency's conclusion that the combined firm will be able to expand its services more rapidly than either company on its own.

AmerisourceBergen Merger Complete, FTC Says Efficiencies Justify Approval

Federal Trade Commission approval of the merger of AmeriSource and Bergen Brunswig reflects the agency's conclusion that the combined firm will be able to expand its services more rapidly than either company on its own.

AmerisourceBergen Merger Complete, FTC Says Efficiencies Justify Approval

Federal Trade Commission approval of the merger of AmeriSource and Bergen Brunswig reflects the agency's conclusion that the combined firm will be able to expand its services more rapidly than either company on its own.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS092326

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel